Diamond standard in diagnostics: nanodiamond biolabels make their mark
Abstract
Fluorescent defects in non-cytotoxic diamond nanoparticles have recently emerged as a preferred candidate for optical labels in biological and medical imaging. The bright fluorescence at 550-800 nm originates from point defects within the particles, some of which appear naturally, while others can be artificially incorporated during synthesis or can be introduced using high-energy ion beam irradiation and subsequent thermal annealing. However, in order for the fluorescent defects to be useful in bio-medical applications there are a number of materials challenges that must be overcome. In this paper, recent studies on nanodiamonds and their use as biolabels are reviewed, while highlighting the links between the physical, chemical and biological issues that arise.
How strong is the evidence?
Evidence Hub reads this as a review, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.